Clinical trials
catalyst calendar across sponsors →Studies where ELMD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 observational
Held by 9 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, Man Group plc, AQR CAPITAL MANAGEMENT LLC, +4 more) · FINRA short interest 1.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 5 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis PopulationNCT04271969observationalQuality of Life (QoL): Quality of Life-Bronchiectasis (QOL-B) questionnaire | — | Completed | Device: SmartVest Airway Clearance System | Bronchiectasis | 25 | 2023-12-01actual | 2023-12-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19